A detailed history of Montag A & Associates Inc transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Montag A & Associates Inc holds 435 shares of VRTX stock, worth $204,571. This represents 0.01% of its overall portfolio holdings.

Number of Shares
435
Previous 385 12.99%
Holding current value
$204,571
Previous $156,000 16.03%
% of portfolio
0.01%
Previous 0.01%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 07, 2024

BUY
$407.69 - $446.08 $20,384 - $22,304
50 Added 12.99%
435 $181,000
Q4 2023

Feb 07, 2024

BUY
$343.0 - $410.68 $68,600 - $82,136
200 Added 108.11%
385 $156,000
Q2 2023

Aug 09, 2023

SELL
$314.42 - $351.91 $943 - $1,055
-3 Reduced 1.6%
185 $65,000
Q4 2022

Feb 02, 2023

BUY
$285.76 - $321.48 $5,429 - $6,108
19 Added 11.24%
188 $54,000
Q4 2020

Feb 12, 2021

BUY
$207.01 - $276.09 $34,984 - $46,659
169 New
169 $40,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $121B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Montag A & Associates Inc Portfolio

Follow Montag A & Associates Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Montag A & Associates Inc, based on Form 13F filings with the SEC.

News

Stay updated on Montag A & Associates Inc with notifications on news.